The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...

SAN DIEGO--(BUSINESS WIRE)--This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first ...

EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in ...

(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has granted clearance to a next-generation ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc (DXCM). (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program ...

Dexcom has kick-started a new, multiyear program that spotlights college athletes with diabetes to inspire others living with the disease to continue playing sports. Maker of continuous glucose ...

Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, and RxFood Corporation, the leader in AI-driven personalized nutrition ...

DexCom recently announced the upcoming U.S. launch of its G7 15 Day Continuous Glucose Monitoring system and received FDA clearance for its Smart Basal insulin dosing optimizer, both targeting ...

DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued. Growth and value investors may find respective ...

Shares of the medical-device maker DexCom (NASDAQ: DXCM) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive ...